This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/company/
n8http://linked.opendata.cz/resource/mesh/concept/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00430/identifier/chebi/
n14http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB00430/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n5http://linked.opendata.cz/resource/drugbank/drug/DB00430/identifier/pharmgkb/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00430/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00430/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00430/identifier/drugbank/
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00430
rdf:type
n3:Drug
n3:description
Cefpiramide is a third-generation cephalosporin antibiotic.
n3:generalReferences
# Wang H, Yu Y, Xie X, Wang C, Zhang Y, Yuan Y, Zhang X, Liu J, Wang P, Chen M: In-vitro antibacterial activities of cefpiramide and other broad-spectrum antibiotics against 440 clinical isolates in China. J Infect Chemother. 2000 Jun;6(2):81-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11810540 # Iakovlev VP, Vishnevskii VA, Khlebnikov EP, Khadin IM, Plavlova MV, Elagina LV, Izotova GN: [Cefpiramide (Tamicin) in the treatment of purulent complications of abdominal surgery] Antibiot Khimioter. 1995 Sep;40(9):30-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8651827 # Sampi K, Hattori M: [Comparative study of cefpiramide + amikacin versus piperacillin + amikacin in granulocytopenic patients: a randomized, prospective study] Gan To Kagaku Ryoho. 1992 Aug;19(9):1315-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1503486
n3:group
approved
n3:halfLife
4.44 hours
n3:indication
For treatment of severe infections caused by susceptible bacteria such as P. aeruginosa.
n3:manufacturer
n10:271B4C8C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00430 n20:DB00430
dcterms:title
Cefpiramide
adms:identifier
n5:PA164748136 n6:Cefpiramide n12:C13376 n17:D01904 n18:59213 n19:DB00430
n3:mechanismOfAction
The bactericidal activity of cefpiramide results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
n3:synonym
Cefpiramido Cefpiramidum Cefpiramide
n3:toxicity
Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.
n3:salt
n7:hasConcept
n8:M0111490
n3:IUPAC-Name
n11:271B4C91-363D-11E5-9242-09173F13E4C5
n3:InChI
n11:271B4C97-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n11:271B4C96-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n11:271B4C93-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n11:271B4C94-363D-11E5-9242-09173F13E4C5
n3:SMILES
n11:271B4C95-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n11:271B4C8F-363D-11E5-9242-09173F13E4C5
n3:logP
n11:271B4CA7-363D-11E5-9242-09173F13E4C5 n11:271B4C8D-363D-11E5-9242-09173F13E4C5 n11:271B4C90-363D-11E5-9242-09173F13E4C5
n3:logS
n11:271B4C8E-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:J01DD11
n3:H-Bond-Acceptor-Count
n11:271B4C9D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n11:271B4C9E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n11:271B4C98-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n11:271B4C99-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n11:271B4C9B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n11:271B4C9A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n11:271B4C9C-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following intramuscular injection.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
70797-11-4
n3:category
n3:Bioavailability
n11:271B4CA3-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n11:271B4CA5-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n11:271B4CA6-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n11:271B4CA2-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n11:271B4CA1-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n11:271B4CA4-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n11:271B4C92-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n11:271B4C9F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n11:271B4CA0-363D-11E5-9242-09173F13E4C5